Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm

New data from the Phase IIIb HARMONIE trial showed Sanofi’s and AstraZeneca’s respiratory syncytial virus antibody candidate nirsevimab exerts a strong protective effect in infants under 12 months, the companies announced Friday.